May 21, 2024

Gyo Sagara Chief Executive Officer Ono Pharmaceutical Co., Ltd. 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka 541-8564 Japan

Re: Ono Pharmaceutical

Deciphera

Co., Ltd.

Pharmaceuticals, Inc.

May 13, 2024

Filed by Topaz

Merger Sub, Inc. and Ono Pharmaceutical Co., Ltd.

File No. 005-90130

Schedule TO-T filed

Dear Gyo Sagara:

 $$\operatorname{\textsc{We}}$$ have reviewed your filing and have the following comments. In some of our

comments, we may ask you to provide us with information so we may better understand your

disclosure.

 $\hbox{Please respond to these comments by providing the requested information or advise us as }$

soon as possible when you will respond. If you do not believe our comments apply to your facts

and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Schedule TO-T filed May 13, 2024; Offer to Purchase

Summary Term Sheet, page 6

1. We note that the capitalized term "Debt Financing Source" is used in this section, without any accompanying definition or cross-reference. Please define capitalized terms the first time they are used, or provide appropriate cross-references to where such terms are defined.

Source and Amount of Funds, page 27

2. Disclose the existence of any alternative financing plans or arrangements in the $\ensuremath{\text{\textsc{o}}}$

event Parent and

Purchaser do not have the necessary funds to pay the offer

consideration and

related fees and expenses. If there are none, so state. Refer to Item

1007(b) of Regulation

M-A. As relevant here, we note your disclosure, on page 28, that

Gyo Sagara
Ono Pharmaceutical Co., Ltd.

May 21, 2024

Page 2

"[t]he definitive Facility Documents have not been finalized and, accordingly, the actual

terms of the Debt Financing may differ from those described in this Offer to Purchase,"

and that "[t]here is a risk that these conditions precedent will not be satisfied and the Debt

Financing may not be funded when required."

The Merger Agreement; Other Agreements, page 35

3. On page 35, refer to the last sentence of the second paragraph under this section. Please ${}^{\circ}$

 $% \left(1\right) =\left(1\right) +\left(1\right) +\left($

agreements, do not constitute public disclosure under the federal

securities laws. For

instance, clarify that information in these agreements should be considered in conjunction $% \left(1\right) =\left(1\right) +\left(1\right)$

with the entirety of the factual disclosure about the parties in their public reports, if any,

filed with the Commission. Additionally, please confirm your understanding that,

notwithstanding the inclusion of this general disclaimer, you are responsible for

considering whether additional specific disclosures of material information regarding

 $% \left(1\right) =\left(1\right) \left(1\right)$ material contractual provisions are required to make the statements included in this filing

not misleading.

4. On page 57, under subsection titled "Offer Conditions," please revise to direct the

shareholders to the correct section. We note that Section 13 is titled $\ensuremath{\text{"The}}$

Recommendation by the Board of Directors of the Company." Certain Conditions to the Offer, page $60\,$

5. Refer to the disclosure in the last paragraph in this section. If an Offer Condition is

triggered $\,$ while the Offer is pending, in our view, the Parent or Purchaser must promptly

inform shareholders whether they will assert the condition and terminate the Offer, or

waive it and continue. Reserving the right to waive a condition $% \left(1\right) =\left(1\right) +\left(1\right) +\left($

to time $\,$ is inconsistent with your obligation in this regard. Please revise the language here

that implies that failing to assert a condition is not a waiver of such Offer Condition, or

advise.

We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please direct any questions to Eddie Kim at 202-679-6943 or David Plattner at 202-551-8094.

FirstName LastNameGyo Sagara Comapany NameOno Pharmaceutical Co., Ltd. Sincerely,

Division of

Office of

Corporation Finance
May 21, 2024 Page 2
Mergers & Acquisitions
FirstName LastName